Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
1.740
+0.040 (2.35%)
Jul 3, 2025, 1:00 PM - Market closed

Aprea Therapeutics Stock Forecast

APRE's stock price has decreased by -54.21% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts that cover Aprea Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $15.5, which forecasts a 790.8% increase in the stock price over the next year. The lowest target is $11 and the highest is $20.

Price Target: $15.5 (+790.8%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $11 $15.5 $20 $20
Change +532.18% +790.80% +1049.4% +1049.4%
* Price targets were last updated on Jan 15, 2025.

Analyst Ratings

The average analyst rating for Aprea Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Feb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy 111111
Buy 111111
Hold 000000
Sell 000000
Strong Sell 000000
Total 222222

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$20
Strong Buy Reiterates $20 +1,049.43% Jan 15, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$20
Strong Buy Reiterates $20 +1,049.43% Dec 17, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$20
Strong Buy Reiterates $20 +1,049.43% Nov 18, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$20
Strong Buy Reiterates $20 +1,049.43% Oct 24, 2024
Wedbush
Wedbush
Buy
Reiterates
$11
Buy Reiterates $11 +532.18% Aug 13, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
667.08K
from 1.50M
Decreased by -55.60%
Revenue Next Year
612.00K
from 667.08K
Decreased by -8.26%
EPS This Year
-1.59
from -2.35
EPS Next Year
-1.39
from -1.59
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
---583.23K1.50M667.08K612.00K20.74M
Revenue Growth
----157.63%-55.60%-8.26%3,289.22%
EPS
-50.61-34.88-67.99-3.95-2.35-1.59-1.39-0.69
EPS Growth
--------
Forward PE
--------
No. Analysts
-----555
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 1.9M 1.9M 62.2M
Avg 667,080 612,000 20.7M
Low n/a n/a n/a

Revenue Growth

Revenue Growth 20252026202720282029
High
25.8%
183.3%
10,057.7%
Avg
-55.6%
-8.3%
3,289.2%
Low - - -

EPS Forecast

EPS 20252026202720282029
High -0.96 -0.77 0.16
Avg -1.59 -1.39 -0.69
Low -2.77 -2.45 -1.54

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.